Finally! Novartis AG To Release Long-Awaited Juliet CAR-T Data In June

After Jefferies analyst Biren Amin said last night that he thought Novartis would be presenting its midstage CAR-T blood cancer data from Juliet at a Swiss conference in mid-June, the Big Pharma has confirmed to FierceBiotech that it will indeed be posting the long-awaited data.

In a note to clients posted last night, Amin said that: “Titles released for the International Conference on Malignant Lymphoma (ICML) indicate that Novartis intends to present the interim look from the phase 2 Juliet trial in DLBCL [diffuse large B-cell lymphoma].”

The Juliet data have already been seen by Novartis and the FDA, with the midstage test assessing its cutting-edge CAR-T med tisagenlecleucel (a.k.a. CTL019) in DLBCL patients–a key battle ground with rival biotech Kite Pharma and its axicabtagene ciloleucel (a.k.a. KTE-C19), as both race to be first to market.

Back to news